type 2 diabetes
Conditions
Interventions
Continuing statin alone: a statin preparation (type unspecified, at a normal dosage)
A combination with EPA: a statin preparation + Epadel of 1,800 mg a day.
Sponsors
The Department of Diabetes, Endocrinology and Metabolism, Tokyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients with type 2 diabetes mellitus, complicated with dyslipidemia and who have given written informed consent to participate in the current study.
Exclusion criteria
Exclusion criteria: Those patients who meet any of the following conditions were excluded from the current study: 1) Currently suffer from cerebral hemorrhage or have had it in the past 2) Have embolism or hemorrhagic infarction 3) Are currently suffering from a hemorrhage (conditions such as hemophilia, capillary fragility, hemorrhage from the digestive system, urinary tract hemorrhage, hemoptysis, and vitreous hemorrhage) 4) Have severe congestive heart failure 5) Have a history of hypersensitivity to statin or components of EPA 6) Have a peptic ulcer 7) Have a severe hematological anomaly 8) Have a severe complication (such as a malignant tumor, liver cirrhosis, renal failure and heart failure) 9) Those who failed to give informed consent 10) Other patients whom the chief investigator or attending physician finds unsuitable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessing endothelial function of patients with type 2 diabetes, using strain-gauge plethysmography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pulse wave velocity(PWV) and intima-media thickness(IMT) of carotid artery echogram before and after EPA administration. | — |
Countries
Japan
Contacts
Public ContactTakashi Miwa
Tokyo Medical University The Department of Diabetes, Endocrinology and Metabolism
Outcome results
None listed